Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

NCT05498272 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
BRCA1 Mutation
BRCA2 Mutation
Prostatic Adenocarcinoma
High-Risk Cancer

Interventions

DRUG: Olaparib
DRUG: LHRH agonist

Sponsor

Rana McKay, MD

Collaborators

[object Object]
[object Object]